Evidence map›Paper›PMID 31127690›Full record

ArticleCancer medicine2019

Clinical analysis of 547 patients with neuroendocrine tumors in a Chinese population: A single-center study.

Lijie Song, Xuejia Zhai, Shunli Yu, Yihui Ma, Feng Wang, Xuxu Yu, Shuang Tao, Yujin Lian, Minjie Yang, Weili Tao and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Lijie SongDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuejia ZhaiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0002-7361-1983
Shunli YuDepartment of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yihui MaDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-0942-075X
Feng WangDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xuxu YuDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shuang TaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID 0000-0003-0386-7841
Yujin LianDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Minjie YangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Weili TaoDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Qingxia FanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeuroendocrine tumors (NETs) are rare, which has resulted in a lack of published data on their epidemiology and clinical features. We therefore aimed to investigate the epidemiology, clinical features, treatments, and prognosis of patients with NETs.

methodsThe clinicopathologic characteristics of 547 patients who were pathologically diagnosed with NETs were retrospectively analyzed, including age, sex, primary and metastatic sites, symptoms, pathology, treatment, and prognosis.

resultsThe 547 patients had a wide age range (9-87 years), with a male to female ratio of 1:1.1. The primary tumor sites included 413 in the digestive system, 74 in the lung, 15 in the mediastinum, 8 in unknown sites, and 37 in other sites. Of the 413 patients with digestive system NETs, the pancreas, rectum, and stomach were the most common primary sites. Blood metastases were found in 84 patients at initial diagnosis, and the liver, bone, and lung were the most frequent sites of metastasis. Lymph node metastases were found in 82 patients at initial diagnosis. Surgery and chemotherapy were the most widely applied treatments. Statistical analysis showed that age <50 years, female sex, lower-grade tumor, no distant metastasis, intestinal NET and surgery indicated a favorable prognosis.

conclusionsA difference between China and other countries is that small intestinal NETs are quite common in other countries but are rare in China. In China, the most common primary sites are the pancreas, rectum, and stomach. Furthermore, no unified treatments exist, though prognoses could be improved by using methods such as surgery, targeted therapies, and somatostatin analogs. CLINICAL

trial registrationThis study was not a clinical trial.

Indexed as

AdolescentAdultAgedAged, 80 and overChildChinaCombined Modality TherapyDisease ManagementFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingNeuroendocrine TumorsPopulation Surveillanceepidemiologyneuroendocrine tumorspathologyprognosistreatments

Identifiers

PMID31127690
PMCPMC6639184
OpenAlexW2945035015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.